Highlights AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 10:05:01 06/03/2026 pm IST			5-day change	1st Jan Change
14,500.00 ^GBX	-1.85%		-6.70%	+5.15%

06/03	AstraZeneca: Strengths remain aptly valued
06/03	Top pharma companies racing to launch a weight-loss pill	RE

Highlights

06/03	AstraZeneca: Strengths remain aptly valued
06/03	Fda says oncologic drugs advisory committee meeting for camizestrant, truqap sNDA to be held on April 30	RE
05/03	Illumina, Inc. and Nashville Biosciences, LLC Announce New Proteomics Data Offering and Expansion of Alliance for Genomic Discovery Dataset	CI
05/03	GLP-1 drugs protect against new or worsening addictions, large study shows	RE
04/03	NervGen Pharma Corp. Announces Executive Changes	CI
02/03	AIM ImmunoTech Signs Agreement for Planning of A Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer	CI
26/02	Mixed start in Europe; Rolls-Royce shares climb	AN
26/02	Arcus Biosciences Provides Pipeline Update on Its Clinical-Stage Investigational Molecules and Discovery Programs	CI
25/02	HSBC reclaims top spot as FTSE 100 hits new high	AN
25/02	GSK to Buy 35Pharma for $950 Million -- Update	DJ
25/02	Iconovo AB (Publ.) and Lonza Signs LOI Regarding Strategic Collaboration	CI
24/02	Avacta hails new data supporting proprietary preCision platform	AN
24/02	Avacta's pre\|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis	CI
23/02	Aim Immunotech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and Astrazeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer	CI
23/02	Stocks fall after latest tariff salvo	AN
20/02	European Stocks Close Higher in Friday Trading; Investors Encouraged by Strong Earnings	MT
20/02	Calquence Plus Venetoclax Approved in the Us as First All-Oral, Fixed-Duration Combination for Patients with Chronic Lymphocytic Leukemia in the 1St-Line Setting	CI
20/02	Novartis to Divest Majority Stake in India Arm Amid Tariff Threats	MT
20/02	Calquence plus venetoclax approved in the US for patients with chronic lymphocytic leukemia in the 1st-line setting	RE
20/02	US regulator FDA greenlights AbbVie and AstraZeneca's cancer treatment	AN
20/02	US Approves AstraZeneca's Combination Treatment for Leukemia, Lymphoma	MT
20/02	Risk on, risk off
19/02	European Medicines Agency Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer	CI
19/02	AstraZeneca, Daiichi Sankyo EU Application Validated for Breast Cancer Treatment	MT
19/02	UK Stocks-Factors to watch on February 19	RE